CYTOSORBENTS CORPORATION - COMMON STOCK

CytoSorbents Reports First Quarter 2024 Results

09 May 2024 15:17:23 By Nasdaq GlobeNewswire

CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe

02 May 2024 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

26 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOSORBENTS CORPORATION - COMMON STOCK

17 Apr 2024 08:45:06 By NetDania Notify

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

17 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOSORBENTS CORPORATION - COMMON STOCK

16 Apr 2024 08:57:39 By NetDania Notify

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

14 Mar 2024 15:39:31 By Nasdaq GlobeNewswire

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

06 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

08 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOSORBENTS CORPORATION - COMMON STOCK

25 Jan 2024 09:26:32 By NetDania Notify

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

17 Jan 2024 06:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOSORBENTS CORPORATION - COMMON STOCK

08 Jan 2024 09:16:09 By NetDania Notify

NetDania - New 12 months Low: CYTOSORBENTS CORPORATION - COMMON STOCK

28 Dec 2023 08:48:08 By NetDania Notify

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

28 Dec 2023 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

13 Dec 2023 08:15:00 By Nasdaq GlobeNewswire

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

09 Nov 2023 15:15:00 By Nasdaq GlobeNewswire

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

27 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents to Present at the 8th Annual Dawson James Conference

05 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

27 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

19 Sep 2023 06:00:00 By Nasdaq GlobeNewswire